If you have been reading about aggregation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
== History == Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. In 2006, Dexcom received U.S. Food and Drug Administration (FDA) approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day sensor that provides up to 288 glucose measurements for every 24 hours. Dexcom received approval of the second-generation product, the Seven Continuous Glucose Monitoring System, in May 2007. This device improved on accuracy and extended use from three to seven days. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation and Animas Corporation as well as a development agreement with Edwards Lifesciences for a continuous glucose monitor in the intensive care unit hospital environment. During February 2009, Dexcom received approval for the Seven Plus Continuous Glucose Monitor, its new continuous glucose monitoring system, from the FDA. This product received a CE mark in November 2009. In 2013, development work for integration with Insulet was discontinued. Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its forthcoming G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. The G5 was approved in 2016 by the FDA for use as a standalone device, while the G6 gained approval in 2018. Dexcom's first G-series CGM, the G4 Platinum, received a CE mark and FDA approval in 2012 for adults ages 18 and over. This device improved hypoglycemic accuracy by 30%.
The main role of the tissue factor (TF) pathway is to generate a "thrombin burst", a process by which thrombin, the most important constituent of the coagulation cascade in terms of its feedback activation roles, is released very rapidly. FVIIa circulates in a higher amount than any other activated coagulation factor. The process includes the following steps:
=== Lymphatic drainage === Lymphatic channels from the posterior half of the scalp drain to occipital and posterior auricular nodes. Lymphatic channels from the anterior half drain to the parotid nodes. The lymph eventually reaches the submandibular and deep cervical nodes.
== Methods == Amino acid racemization analysis consists of sample preparation, isolating the amino acid wanted, and measuring its D:L ratio. Sample preparation entails the identification, raw extraction, and separation of proteins into their constituent amino acids, typically by grinding the sample followed by acid hydrolysis. The amino acid derivative hydrolysis product can be combined with a chiral specific fluorescent, separated by chromatography or electrophoresis, and the particular amino acid D:L ratio determined by fluorescence. Alternatively, the particular amino acid can be separated by chromatography or electrophoresis, combined with a metal cation, and the D:L ratio determined by mass spectrometry. Conventional racemization analysis tends to report a D-alloisoleucine / L-isoleucine ratio (A/I or D/L ratio). This stereoisomer pair has the advantages of being relatively easy to measure and being chronologically useful through the Quaternary. Reversed phase HPLC techniques can measure up to 9 amino acids useful in geochronology over different time scales on a single chromatogram (aspartic acid, glutamic acid, serine, alanine, arginine, tyrosine, valine, phenylalanine, leucine). Amino acid dating relies on the assumption that the fraction of amino acids being studied has been a closed system since its formation, exchanging nothing with its surroundings. Removing amino acids that have diffused into the sample from its surroundings decreases variability in results by ensuring that analysis is performed only on the most representative fraction of amino acids.
=== Diplomats === Hamzat Ahmadu - Nigerian diplomat, former ambassador to the Soviet Union, the United States of America and high commissioner to the Bahamas. Nuhu Bamalli - Former minister of foreign affairs Mohammed Sanusi Barkindo – 28th Secretary-General of OPEC. Ibrahim Gambari – (Fulani/Yoruba); Scholar and diplomat; Chief of Staff to the president; Under-Secretary-General / Special Adviser – Africa United Nations; former minister of foreign affairs, current chief of staff to the president of Nigeria. Amina J. Mohammed – (Fulani/English); Politician; Deputy Secretary-General of the United Nations; former Federal Minister of Environment, Nigeria. Tijjani Muhammad-Bande – Political scientist, administrator and career diplomat. Current president of the United Nations General Assembly, Permanent Representative of Nigeria to the UN, former VP of the UN General Assembly. Nura Abba Rimi - Nigeria's ambassador to the Arab Republic of Egypt, with concurrent accreditation to the State of Palestine and the State of Eritrea; former Presidential Liaison Officer. Ibrahim Sulu-Gambari – (Fulani/Yoruba); Nigerian judge and monarch. Current Emir of Ilorin, Nigeria. Yusuf Tuggar – Minister of Foreign Affairs. Aminu Bashir Wali - Former permanent representative to the United Nations, former minister of foreign affairs. Isa Wali - former Nigerian high commissioner to Ghana.
Sources: en.wikipedia.org
On 20 August 2020, Russian opposition leader Alexei Navalny fell ill during a flight from Tomsk to Moscow. The plane made an emergency landing in Omsk, where Navalny was hospitalized and put in a medically induced coma. His family suspected his illness was caused by a poison put into a cup of tea he drank before the flight. He was evacuated to the Charité hospital in Berlin, Germany, the following day. On 2 September, the German government said that it had "unequivocal evidence" that Navalny was poisoned by a Novichok agent after tests at a German military lab and had called on the Russian government for an explanation, with labs in France and Sweden corroborating the findings. On 4 September, the North Atlantic Council was briefed by the German representative on the "appalling assassination attempt on" Navalny. In a post-meeting press conference, Secretary-General Jens Stoltenberg said that NATO allies "agree that Russia has serious questions it must answer", that the OPCW needed to conduct an impartial investigation, that "those responsible for this attack must be brought to justice" and called on Russia to "provide complete disclosure of the Novichok programme to the OPCW." Navalny had been out of his coma since 7 September. On 6 October, the OPCW confirmed the presence of a cholinesterase inhibitor from the Novichok group in Navalny's blood and urine samples. At the same time, the OPCW report clarified that Navalny was poisoned with a new type of Novichok, which was not included in the list of controlled chemicals of the Chemical Weapons Convention.
White House National Security Advisor Jake Sullivan responded to the report saying there was still "no definitive answer" to the question of the pandemic's origins. On 28 February 2023, the head of the Federal Bureau of Investigation (FBI), Christopher Wray, said the bureau believes Covid-19 most likely originated in the lab. The FBI concluded with "moderate confidence" that COVID-19 may have been created in a laboratory, based in part on genomic analysis conducted by scientists at the National Center for Medical Intelligence. On 20 March 2023, the COVID-19 Origin Act of 2023 was signed into law. On 23 June 2023, the Biden administration released its report, as required by the Act.
=== Composite === As described above the properties of the nanocellulose makes an interesting material for reinforcing plastics. Nanocellulose can be spun into filaments that are stronger and stiffer than spider silk. Nanocellulose has been reported to improve the mechanical properties of thermosetting resins, starch-based matrixes, soy protein, rubber latex, poly(lactide). Hybrid cellulose nanofibrils-clay minerals composites present interesting mechanical, gas barrier and fire retardancy properties. The composite applications may be for use as coatings and films, paints, foams, packaging.
==== Military service (1954–55) ==== With the Korean War occurring, Mizell had been drafted to serve in the United States Army as early as 1952, but he managed to get his service deferred twice because he was the support for his mother and grandmother. Finally, shortly after the 1953 season ended, he reported to Fort McPherson, Georgia, where he would be stationed for the next two years. Mizell, who walked with a "two-furrow" stride, had to make a special effort not to step on the heels of the soldier in front of him when he was marching in ranks. He saw no combat, instead winning 36 games (with only two losses) for the fort's baseball team. Mizell threw four no-hitters and 16 shutouts, helping the team reach the Army baseball championship tournament at Fort Belvoir, Virginia, in 1955. A sergeant by the time he was discharged, Mizell had struck out 324 batters in two years of service.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the standard technique for purity and content. Mass spectrometry provides orthogonal confirmation of identity. The two are normally used together rather than in isolation.